L-[1-13C]phenylalanine oxidation as a measure of hepatocyte functional capacity in end-stage liver disease

American Journal of Surgery

Volumn 173, Issue 4, 1997, Pages 270-273

  Burke, Peter A ^a,b   Stack, Jennifer A ^b   Wagner, David ^b   Lewis, David W ^a   Jenkins, Roger L ^a   Forse, Robert A ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b METABOLIC SOLUTIONS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; PHENYLALANINE; PROTHROMBIN; TYROSINE;

ADULT; ALBUMIN BLOOD LEVEL; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; BREATH ANALYSIS; CLINICAL PROTOCOL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; HUMAN; LIVER CELL; LIVER FAILURE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; CYTOSOL; FEASIBILITY STUDY; LIVER DISEASE; LIVER FUNCTION TEST; METABOLISM; METHODOLOGY; MIDDLE AGED; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY;

ADULT; BREATH TESTS; CYTOSOL; FEASIBILITY STUDIES; HUMANS; LIVER DISEASES; LIVER FUNCTION TESTS; MIDDLE AGED; OXIDATION-REDUCTION; PHENYLALANINE;

EID: 0031114911     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(96)00392-3     Document Type: Article

References (30)

1. McIntyre N. The limitations of conventional liver function tests. Semin Liver Dis. 1983;3:265-274.
2. 14C-aminopyrine. Effects of phenobarbital, disulfirm and portal cirrhosis. NEJM. 1974;291:1384-1388.
3. 2 breath analysis as a measurement of demethylation of stable isotope labeled aminopyrine in man. Clinica Chimica Acta. 1978;84:153-162.
4. 14C]phenacetm breath test to measure hepatic function in man. Hepatology. 1984;4:47-52.
5. 13C]Methacetin breath test for evaluation of liver damage. Di Dis Sci. 1987;32:344-348.
6. Renner E, Wietholtz H, Huguenin P, et al. Caffeine: a model compound for measuring liver function. Hepatology. 1984;4:38-46.
7. Oellerich M, Raude E, Burdelski M, et al. Monethylglycinexylide formation kinetics: a novel approach to assessment of liver function. J Clin Chem Clin Biochem. 1987;25:845-853.
8. Rosenthal SM, White EC. Studies in hepatic function. The pharmacological behavior of certain phthalein dyes. The value of selected phthalein compounds in the estimations of hepatic function. J Pharmacol Exp Ther. 1924;24:265-272.
9. Hunton DB, Bollman JL, Hoffman HN. The plasma removal of indocyanine green and sulfobromophthalein: effect of dosage and blocking agents. J Clin Invest. 1961;40:1648-1658.
10. Jost G, Wahllander A, Mandach U, Preisig R. Overnight salivary caffeine clearance: a liver function test suitable for routine use. Hepauilogy. 1987;7:338-344.
11. Henderson JM, Kutner MH, Bain RP. First order clearances of plasma galactose: the effect of liver disease. Gastroenterology. 1982;83:1090-1096.
12. Schneider JF, Baker AL, Haines NW, et al. Aminopyrine N-demethylation: a prognostic test of liver function in patients with alcoholic liver disease. Gastroenterology. 1980;791:1145-1150.
13. Saunders JB, Lewis KO, Paton A. Early diagnosis of alcoholic cirrhosis by the aminopyrine breath test. Gastroenterology. 1980;79:112-114.
14. Monroe PS, Baker AL, Schneider JF, et al. The aminopyrine breath test and serum bile acids reflect histologic severity in chronic hepatitis. Hepatology. 1982;2:317-322.
15. Baker AL, Kotake AN, Schoeller DA. Clinical utility of breath tests for the assessment of hepatic function. Semin Liver Dis. 1983;3:318-329.
16. Lewis KO, Nicholson G, Lance P, Paton A. Aminopyrine breath test in alcoholic liver disease and in patients on enzyme-inducing drugs. J Clin Pathol. 1977;30:1040-1043.
17. Schoeller DA, Kotake AN, Lambert GH, et al. Comparison of the phenacetin and aminopyrine breath tests: effect of liver disease, inducers and cobaltous chloride. Hepatology. 1985;5:276-281.
18. Wang RIH, Jacobson J. Adverse reactions to sulfobromophthalein sodium. Amer J Med Sci. 1966;11:973-976.
19. Skak C, Keiding S. Methodological problems in the use of indocyanine green to estimate hepatic blood flow and ICG clearance in man. Liver. 1987;7:155-162.
20. Iber FL, Rosen H, Levenson SM, Chalmers TC. The plasma amino acids in patients with liver failure. J Clin Lab Med. 1967;50:417-425.
21. Levine RJ, Conn HO. Tyrosine metabolism in patients with liver disease. J Clin Invest. 1967;46:2012-2020.
22. O'Keefe SJD, Abraham R, El-zayadi A, et al. Increased plasma tyrosine concentrations in patients with cirrhosis and fulminant hepatic failure associated with increased plasma tyrosine flux and reduced hepatic capacity. Gastroenterology. 1981;81:1017-1024.
23. Hehir DJ, Jenkins RL, Bistrian BR, et al. Abnormal phenylalanine hydroxylation and tyrosine oxidation in a patient with acute fulminant liver disease with correction by liver transplantation. Gastroenterology. 1985;89:659-663.
24. Shanbhogue RLK, Bistrian R, Laksham K, et al. Whole body leucine, phenylalanine and tyrosine kinetics in end stage liver disease before and after hepatic transplantation. Metabolism. 1987;36:1047-1053.
25. Clowes GHA, McDermott WV, Williams LF, et al. Amino acid clearance and prognosis in surgical patients with cirrhosis. Surgery. 1984;96:675-684.
26. Pearl RH, Clowes GHA, Silvano B, et al. Amino acid clearance in cirrhosis. Arch Surg. 1987;122:468-473.
27. 13C]phenylalanine. Am J Physiol. 1990;259:E835-E843.
28. Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the esophagus for bleeding esophogeal varices. Br J Surg. 1973;60:646-649.
29. Heberer M, Talke H, Maier KP, Gerok W. Metabolism of phenylalanine in liver disease. Klin Wochenschr. 1980;58:1189-1196.
30. Rudman D, DiFulco TJ, Galambos JT, et al. Maximal rates of excretion and synthesis of urea in normal and cirrhotic subjects. J Clin Invest. 1973;52:2241-2249.